InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Smith L. Mary, Directrice du Développement. Director active across 2 companies, notably SpringWorks Therapeutics, Inc.. Aggregated, 10 reports have been published. The latest transaction was disclosed on 7 January 2022 (Retenue fiscale). Regulator: SEC (Form 4). All data is free.
Declarations10 total
€58,6061,181 shares@ €49.624331.5% of flow
Common Stock
SEC:0001104659-22-004463·
€58,6061,181 shares@ €49.624315.8% of flow
Common Stock
SEC:0001104659-22-004463:0·
€87,9341,772 shares@ €49.624347.3% of flow
Common Stock
SEC:0001104659-22-003144·
€87,9341,772 shares@ €49.624323.7% of flow
Common Stock
SEC:0001104659-22-003144:0·
22,205 shares
Common Stock
SEC:0001104659-22-002747·
22,205 shares
Common Stock
SEC:0001104659-22-002747:0·
€19,82810,000 shares@ €1.982810.7% of flow
Common Stock
SEC:0001104659-21-125932·
€19,82810,000 shares@ €1.98285.3% of flow
Common Stock
SEC:0001104659-21-125932:0·
€19,53210,000 shares@ €1.953210.5% of flow
Common Stock
SEC:0001104659-21-092123·
€19,53210,000 shares@ €1.95325.3% of flow
Common Stock
SEC:0001104659-21-092123:0·
10 of 10 declarations
About Smith L. Mary
Mary L. Smith serves as the Chief Development Officer at SpringWorks Therapeutics, Inc. She oversees the company's strategic development initiatives, focusing on innovation and growth. Smith brings expertise in business development and project management, contributing to guiding the company's direction. Her commitment to operational excellence supports SpringWorks' mission.
